Abstract: Stable suspension compositions including cucurbiturils. More particularly, the stable suspension compositions including cucurbituril particles suspended in a medium. Also, the preparation of the suspension composition and a method of counteracting malodour including application of the suspension composition to a source of malodour.

Abstract: The present invention relates to a sprayable composition for providing a translucent, transparent, semi-transparent or opaque sprayable hair product which exhibits a high level of hold and rigidity to hair such that hair can be held in a particular position for prolonged periods of time without unnatural hardness, superior retention of shape in conditions of heat and humidity, and imparting thickness and body compared to current hairsprays; the composition comprising: a propellant and at least one binder, wherein at least one binder comprises an ethylene vinyl alkanoate copolymer with a weight percent of vinyl alkanoate in the copolymer within the range of 19 wt % to 42 wt %.

Abstract: An oil-in-water type emulsion and a cosmetic composition having the same to an oil-in-water type emulsion in which an oil-phase part having a C12-C22 fatty acid, an oil and an emulsifier is dispersed in a water-phase part comprising a viscosity increasing agent, a neutralizing agent and water is disclosed. The wherein the oil-in-water type emulsion has a starch-based viscosity increasing agent as the viscosity increasing agent A cosmetic composition having the same is also disclosed. In spite of being an emulsified composition obtained through the neutralization of fatty acids, the oil-in-water type emulsion according to the present invention has excellent stability and is also excellent in view of the feeling of use, skin irritation, and stability on the skin, and thus enables the manufacture and use of various formulations of chemical products.

Abstract: A silicone emulsion free of a surfactant and an emulsifier is disclosed. The emulsion includes a dispersed oil phase having a polyorganosiloxane with one or more hydroxyl groups in a continuous aqueous or anhydrous organic diol phase including an anionic polymer.

Abstract: The present invention relates to an oral care composition for use in the treatment or prevention of erosive tooth demineralization, plaque, and caries. This oral care composition includes zinc lactate dihydrate, a stannous ion source, at least one phosphate salt, and a buffer system.

Abstract: The present disclosure relates to hair treatment agents for reducing and/or preventing the bleeding and/or fading of artificially created hair colours, which agents comprise an aqueous cosmetic carrier, and (a) have a pH value ranging from about 3.5 to about 6.0, and (b) contain at least one alkaline earth salt of a dicarboxylic acid having from about 2 to about 8 C atoms. Further subjects of the present disclosure are a method and a multi-component packaging unit in which the aforesaid hair treatment agents are used. A further subject of the present disclosure is the use of a corresponding hair treatment agent for protecting the colour of dyed hair.

Abstract: The present invention is a chemical formulation and method of using the chemical formulation to neutralize or eliminate odors on a surface. In one aspect, the chemical formulation is an aqueous solution of multi-valent citrate salts and a surfactant that may further comprise a fragrance and/or a color and/or a chelating agent. The method comprises the steps of applying this formulation in sufficient volume to saturate the surface thereby neutralizing or eliminating the odor. In another aspect, the formulation of multi-valent citrate salts may be applied in solid form to an odorous aqueous solution or may be used to coat an absorbent matrix that is expected to receive an odorous aqueous solution.

Abstract: Disclosed is the use of (A) an ester of levulinic acid with a fatty alcohol as solubilizing agent for oil soluble organic UV filters (B).

Abstract: The present invention relates to an exopolysaccharide-protein complex obtained from a bacterium comprising: (i) a crude exopolysaccharide, and (ii) exopolysaccharide-associated proteins which are derived from outer membrane vesicles and have a molecular weight between 30 and 250 kDa. The present invention further relates to a method for preparing said exopolysaccharide-protein complex and uses thereof.

Abstract: The present invention concerns the use, for the production of a cosmetic or dermatological composition comprising at least one aqueous phase, of a branched or crosslinked polymer obtained by polymerization of an aqueous solution of one or more monomers in water-in-oil inverse emulsion, at least one of the monomers used being an acrylic monomer and one or more of the monomers used being a monomer bearing at least one weak acid function, the molar percentage of monomers bearing at least one weak acid function relative to all of the monomers used being at least 30 mol %, characterized in that: i) the polymerization is carried out with a concentration of all the monomers in aqueous solution lying in the range 1.3 mmol to 3.

Abstract: A method of reducing the level of melanin in the skin of a subject is disclosed wherein an efficacious amount of Chinese Lantern oil is applied to the skin.

Abstract: A method comprising topically applying to facial skin a composition comprising an aqueous, alcoholic, or aqueous-alcoholic extract from Nymphoides peltatum.

Abstract: A method of reducing the appearance of hyperpigmented skin or inflamed skin is disclosed. The method can include topically applying to hyperpigmented skin or inflamed skin a composition comprising an effective amount of an extract of Rhododendron ferrugineum leaf to reduce melanocyte pigmentation in the skin or to reduce tumor necrosis factor alpha (TNF-?) and cyclooxygenase-1 and -2 (COX-1 and COX-2) activity in the skin.

Abstract: Methods in which an extract of Salvia miltiorrhiza roots is applied to the skin for a soothing cosmetic topical treatment. The invention also concerns a particular extract of Salvia miltiorrhiza roots, as well as compositions containing this extract and a cosmetic treatment method providing a soothing effect to the skin.

Abstract: Disclosed is a dissolvable film adapted to adhere to an oral mucosal tissue of a subject, wherein the film comprises at least three indigestible hydrophilic polymers constituting from 35% to 55% of the film dry weight and wherein the at least three polymers comprise xanthan gum and carboxymethyl cellulose (CMC) in a weight ratio of between 1:0.8-1.6, and at least one other cellulose based polymer. Optionally, the film may further include an active agent in an amount of 0.01% to 35% of the film dry weight. Disclosed also is a method for preparing the film and a method for treating or preventing oral conditions comprising implementing the film. Particularly, the film may be applied between dentures and the gums of the user.

Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

Abstract: Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X-rays and/or scintillation. Optionally, the photosensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and/or inorganic nanoparticles in photodynamic therapy or in X-ray induced photodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and/or one or more chemotherapeutic agent.

Abstract: A compounded topical composition may include an antiviral component, a topical base component, and a local anesthetic component. The antiviral component may include fine powder obtained by grinding oral tablets of one or more antiviral actives. The topical component may include the local anesthetic component. The local anesthetic component may be present in an amount between about 2% and about 8% by weight of the compounded topical composition and the antiviral component may be present in an amount between 4% and 12% by weight of the compounded topical composition. The antiviral component may include acyclovir, valaciclovir, penciclovir, famciclovir, or combinations thereof, and the topical base component may be a lidocaine topical, a lidocaine and prilocaine topical, or both.

Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).

Abstract: Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax (Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.

Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising naltrexone are provided. Formulations and methods of treating alcohol use disorder and related conditions with the drug products are also provided.

Abstract: The present invention relates to the field of drug delivery and, particularly, to alternative processes for preparing ophthalmic compositions of Brinzolamide or pharmaceutical acceptable salts thereof.

Abstract: An ophthalmic composition useful for the treatment of bacterial eye infections is provided. The ophthalmic composition includes the suspension of particles of active anti-bacterial agent in a gelled matrix.

Abstract: Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.

Abstract: In some aspects, the present disclosure provides dosage forms, such as oral drug dosage forms, configured to provide a desired release profile, the dosage forms comprising a multi-layered structure comprising a plurality of layers of a first erodible material admixed with a compound (e.g., a drug) or a reagent, wherein the first erodible material is embedded in a second material not admixed with the compound (e.g., the drug) or the reagent. In other aspects, the present disclosure provides methods of designing, such as obtaining a thickness and/or surface area of a layer comprising an erodible material admixed with a compound (e.g., a drug) or a reagent, and/or amount of the compound (e.g., the drug) or the reagent admixed in the erodible material, and methods of making, such as three-dimensional printing, dosage forms configured to provide desired release profiles.

Abstract: The present invention relates to the oral pharmaceutical composition comprising an androgen receptor inhibitor and one or more pharmaceutically acceptable excipients selected from the group comprising of fillers/vehicles, solvents/co-solvents, preservatives/antioxidants, surfactants, buffering agents, chelating agents, sweetening agents, flavouring agents, sweetness/flavour enhancing agents, or combinations thereof. The present invention also relates to the processes for the preparation of the oral pharmaceutical composition comprising androgen receptor inhibitor and one or more pharmaceutically acceptable excipients.

Abstract: The invention includes a toothpaste or other orally applied product to be used at least once daily to help prevent or inhibit the acquisition of a number of infections by oral or pharyngeal tissues, particularly including the “common” cold. These compositions possess a combination of ingredients that is not found in other toothpastes or other orally applied products, and these ingredients work together to synergistically interfere with the acquisition of a number of pathogens. The toothpastes will have the usual dentifrice ingredients known to prevent tooth decay, as well as those that reduce halitosis (i.e., bad breath), and prevent gingivitis. In addition, the toothpastes will include one or more of: 1) GALALCOOL® as an individual compound, and not as an extract component; 2) zinc protoporphyrin IX; and 3) one or more other colorless or low-color tannin(s) each as an individual compound, and not as an extract component.

Abstract: The present invention comprises buffered compositions and methods for antiseptically treating or pretreating anatomic surfaces for invasive surgical or treatment procedures. The compositions and methods according to the present invention find use in treating skin, gums and ocular surfaces for injections and other procedures. The buffered compositions of the present invention comprise antiseptic agents, optionally within an aqueous gel or semi-gel formulation, to provide enhanced methods of treating anatomic surfaces such as the gums or eye prior to surgical or other invasive procedures. Buffered compositions provide additional benefits to standard non-buffered preparations including decreased toxicity to the anatomic surfaces, which improves post-procedural discomfort and vision in the case of ocular surfaces.

Abstract: Topical formulations to treat skin conditions, such as psoriasis, are provided in which a polymer conjugate of an indolocarbazole exhibits reduced systemic exposure. An example formulation includes the TrkA antagonist, SNA-120, together with a preservative/antioxidant, a preservative/solvent, a solvent, a solvent/moisturizing agent, a stiffening agent, and one or more emollients/emulsifying agents.

Abstract: Disclosed are self-foaming compositions, comprising a heavy cream product and a propellant, which are admixed, and may be used to produce a foam for use in pharmaceutical, dermatological, and cosmetic applications.

Abstract: Compositions and methods for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder are described herein. The compositions contain a nanolipogel for sustained delivery of an effective amount of one or more active agents of choice, preferably a drug for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder. The nanolipogel includes a lipid bilayer surrounding a hydrogel core, which may optionally include a host molecule, for example, an absorbent such as a cyclodextrin or ion-exchange resin. In preferred embodiments at least one of active agents is an immunosuppressant.

Abstract: The present invention relates to pharmaceutical formulations, in particular FVIII formulations. The present invention furthermore relates to methods for producing such compositions.

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.

Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein “Ra” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.

Abstract: Disclosed are novel pharmaceutical compositions containing 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid his-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

Abstract: An oral pharmaceutical composition comprising a drug and one or more pharmaceutically acceptable excipients in a monolithic dosage form, wherein the dosage form is configured such that when the dosage form is divided into more than one piece and at least one of the pieces is administered to a subject the Cmax, AUC, and/or rate of drug released after administration is substantially the same or lower and the Tmax is higher than the Cmax, AUC, rate of drug released, and/or Tmax after administration of: (1) a comparable composition in intact dosage form of equal drug dosage of the administered at least one piece; (2) a bioequiva lent drug composition in an intact dosage form of equal drug dosage to the administered at least one piece; and (3) a divided piece of a bioequivalent drug composition, wherein the divided piece comprises a drug dosage equal to the dosage of the administered piece of the oral composition. Methods of making the same and methods of using the same are also provided.

Abstract: The present disclosure relates to an oral, immediate release, abuse deterrent pill containing at least one active pharmaceutical ingredient susceptible to abuse which is homogenously spread throughout a carrier matrix used to deter abuse. The pill is prepared using hot melt extrusion and a forming unit through a continuous process. The formed pill is abuse deterrent to parenteral administration due at least to particle size, viscosity, or purity limitations.

Abstract: Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt an pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position.

Abstract: The present invention provides methods and liposomal compositions useful in therapeutics, and diagnosis, prognosis, testing, screening, treatment and/or prevention of various disease conditions. The present invention provides imaging methods for various conditions. The present invention is a multi-layered drug delivery pathway, inclusive of nanoparticle liposomal formulations and mechanisms of localized action via unzipping upon delivery to the affected tissue site. The nano-encapsulation methodology allows maximization a potent antioxidant's biocompatibility, increased target cell penetration and uptake, reduced off-target effects and retention of high anti-oxidative activity for promising therapeutic potential.

Abstract: Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.

Abstract: A nonaqueous adhesive skin patch at least comprises a backing film and an adhesive layer placed thereabove, the adhesive layer containing a local anesthetic, wherein when the total mass of an adhesive is set to 100% by mass, the adhesive layer includes the following in the ratio of: 20 to 40% by mass of an elastomer; 20 to 35% by mass of a softener; 20 to 40% by mass of a resin; 3.0 to 7.0% by mass of the local anesthetic; and 0.3 to 4.0% by mass of organic acid, and wherein the adhesive layer has a mass per unit area of 100 to 200 g/m2.

Abstract: In one embodiment, a drug is administered to a subject using a transdermal patch that includes a substrate and a layer of pressure-sensitive adhesive provided on the substrate, the pressure-sensitive adhesive comprising a blend of an adhesive compound and a carrier-drug compound, the carrier-drug compound comprising a drug transport compound and a drug that is to be delivered to the skin of the subject, wherein the drug transport compound transports the drug through the pressure-sensitive adhesive to the skin.

Abstract: This invention discloses anti-bacterial and anti-fungal compositions in spray form, in cream form, in liquid form, and in powder form. The anti-bacterial and anti-fungal compositions comprise cannabinoids, specifically cannabidiol, cannabigerol, tetrahydrocannabinol, tetracannabidivarin, and/or cannabidivarin for anti-bacterial and anti-fungal activities. The anti-bacterial and anti-fungal compositions may be used to treat toe nail fungus, MRSA infection, herpes virus infection, tinea pedis, burn wound infections, sun burns, diabetic infections, eczema, impetigo, dermatophytosis, psoriasis, itchy skin, atopic dermatitis, dandruff, and general topical infections.

Abstract: Micronized trans-resveratrol is provided in 50-200 mg unit dosage form for use as a single unit dose daily for administration to human patients the treatment or prevention of non-alcoholic fatty liver disease and/or for the treatment, prevention or reversal of non-alcoholic hepatic steatosis, e.g. for administration to patients exhibiting evidence of fatty liver on ultrasonography. A reported study shows the effects of resveratrol micronized formulation in reducing the liver fat, decreasing hepatic enzymes, serum glutamate pyruvic transaminase (SGPT) and gamma-glutamyl transpeptidase (g-GT) and decreasing insulin resistance. At the end of the study, statistical analysis showed a strongly statistically significant reduction in the liver fat, which in some patients continued for an extended period after treatment was discontinued.

Abstract: The nutrient mixture made up of vitamin, carotenoid, micronutrient, essential trace element, and plant extract was much more effective in proactively protecting the corneal cells (human) and retinal pigment endothelial cells (rat) against damaging effects of H2O2 and glycosylated proteins (AGE-BSA) compared to its individual components. A mixture is made up of vitamin A, vitamin C, vitamin E, Lycopene, lutein, marigold flower extract, a saffron extract, pine bark extract, grape seed extract, bilberry extract, lipoic acid, L-Arginine and zinc.

Abstract: A method for preventing and treating viral infection and tumor using a drug composition having a benzophenone compound and analogues thereof having a symmetrical core structure and having same or different number of hydroxyl substitutions in benzene rings. The drug preparation for preventing and treating HIV, herpes virus and papillomavirus infection and the diseases induced thereby, wherein such viral infections include AIDS, genital warts, flat warts, common warts, herpes simplex, herpes zoster, vaginitis, cervicitis, cervical erosion and senile dementia, as well as cervical cancer, lung cancer, gastric cancer and colon cancer induced thereby. Preparation of hydroxy-substituted benzophenones and analogues thereof together with various compatible excipients into different medicaments or personal disinfected sanitary articles.

Abstract: A formulation comprising at least one ketogenic source, at least one vitamin, at least one mineral, at least one antioxidant, optionally at least one phytonutrient, and optionally at least one other nutrient, and mixtures and combinations thereof intended for the prevention and mitigation of migraine headache.

Abstract: The present invention provides methods and compositions for treating advanced stage non-small cell lung cancer by cyclohexenone compounds.

Abstract: Provided are applications of spermine and derivatives thereof. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain compounds capable of effectively interfering with PAICS activity, reducing SAICAR synthesis, and ultimately reducing SAICAR accumulation, in order to achieve the goal of treating or reducing ADSL deficiency. A better effect in the treatment or improvement of ADSL deficiency is expected from the joint use of at least two of the described compounds.